Innexus Nutraceuticals will be at Vitafoods Europe 2019 – find them on their new distributor IMCD’s stand H64

New Delhi, April 10, 2019: Netherlands-based Innexus Nutraceuticals will be present at the booth of its new distributor, IMCD, at Vitafoods Europe 2019. Exhibiting on Stand H64, Innexus will showcase OptiPEA®, the natural pain relief solution.

The strategic partnership will be more widely available to European supplement manufacturers (Scandinavian countries excluded). With demand rising for alternatives to pain relief drugs, OptiPEA® is a safe and reliable nutraceutical solution. It is palmitoylethanolamide (PEA), a naturally occurring bioactive lipid which has consistently been shown to deliver positive results without negative side effects.

OptiPEA® is produced sustainably from RSPO-certified palmitic acid and manufactured entirely in Europe using a patented GMP production process. It is an excellent alternative to Cannabidiol (CBD), which has recently been classified by the EU as a ‘novel food’, creating uncertainty around its status in the supplements sector. OptiPEA® is also a better alternative to CBD because it is a single molecule and therefore much easier to measure into precise doses. In addition, it has a consistent quality and its origin is completely, transparent and sustainable.

Samuel Zonneveld, CEO at Netherlands-based Innexus, said: “Teaming up with IMCD is a golden combination. The availability of IMCD’s sales capacity, technical support and distribution network will be the next big step for OptiPEA®. Choosing IMCD over other distributors was an easy choice for us as IMCD has a clear vision and method of adding extra value to OptiPEA®.”

Cameron Richardson, IMCD Nutraceuticals Market Manager commented: “Selecting innovative specialty ingredients is at the core of IMCD’s strategy, and that is why we are very pleased to add OptiPEA® to our portfolio. Innexus Nutraceuticals has taken extra steps to develop a PEA product with unique features. When everyone else was focusing on CBD, we had a clear vision for OptiPEA® as a viable alternative from a scientific and regulatory perspective.”

Corporate Comm India(CCI Newswire)